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ScienceDirectNine genetic diseases arise from expansion of CAG repeats in
seemingly unrelated genes. They are referred to as
polyglutamine (polyQ) diseases due to the presence of
elongated glutamine tracts in the corresponding proteins. The
pathologic consequences of polyQ expansion include
progressive spinal, cerebellar, and neural degeneration. These
pathologies are not identical, however, suggesting that
disruption of protein-specific functions is crucial to establish
and maintain each disease. A closer examination of protein
function reveals that several act as regulators of gene
expression. Here we examine the roles these proteins play in
regulating gene expression, discuss how polyQ expansion may
disrupt these functions to cause disease, and speculate on the
neural specificity of perturbing ubiquitous gene regulators.
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Introduction
The search for causative mechanisms among polyQ dis-
eases continues and, at this time, it remains unclear whether
the associated genes impact different points within the
same biological pathway, or whether they ultimately affect
neurodegeneration via different routes. Many hypotheses
regarding the mechanism of polyQ disease have been
postulated, one being that dysregulation of transcription
is causative. Our understanding, however, of the mechan-
isms underlying transcriptional and post-transcriptional
deregulation in polyQ disease remains incomplete. Thus,
we are unable to weigh the contribution of imbalanced gene
expression to the corresponding pathology.
Previous studies comparing gene expression profiles
among PolyQ disease models have found genes commonlyCurrent Opinion in Genetics & Development 2014, 26:96–104 misregulated between diseases, but none have revealed
the genes or pathways responsible for neurodegeneration
[1,2]. Additionally, it is not clear which changes in gene
expression in these early studies reflected primary or
secondary effects. Therefore, the questions remain: Is
misregulation of crucial genes causative in each polyglu-
tamine disease? Is misregulation of these genes common to
multiple diseases? Can we develop therapeutic interven-
tions to alleviate the consequences of misregulated
gene expression? Here we review the evidence for
polyQ-mediated effects on transcriptional regulation and
chromatin modification, and consequent transcriptional
dysregulation in polyglutamine diseases.
Polyglutamine expansion diseases and
regulation of gene expression
Nine inherited neurodegenerative diseases are a con-
sequence of genetic instability that leads to expansion
of CAG repeats in seemingly unrelated genes (Table 1).
These CAG repeats cause expanded polyglutamine tracts
(polyQ) in the corresponding proteins. Repeat length
increases intergenerationally, and increased repeat length
correlates with increased severity of disease and reduced
time to onset of disease symptoms. PolyQ diseases mani-
fest as progressive degeneration of the spine, cerebellum,
brain stem and, in the case of spinocerebellar ataxia 7
(SCA7), the retina and macula. Though they all lead to
neural degeneration, different diseases are initially diag-
nosed by very specific symptoms and patterns of neuronal
death. As these diseases progress, extensive neurodegen-
eration can lead to overlapping patterns of cell death [3].
Currently, no effective treatment for these fatal diseases
is available [4] (Table 2).
Early histological and immunohistological analyses
showed that polyglutamine-expanded proteins, or even
a polyglutamine stretch alone, can form intranuclear
aggregates that contain transcriptional regulatory proteins
[5]. Titration of these factors seemed a likely cause of
polyQ toxicity, but some studies have suggested that
these inclusions may sometimes play a protective role
[6]. Furthermore, inclusions are not observed in SCA2
[7,8], and intranuclear inclusions are not necessarily
indicative or predictive of cell death in polyQ models
and patient samples. In addition, although the essential
lysine acetyltransferase (KAT) and transcriptional coac-
tivator cAMP-response element-binding (CREB) binding
protein (CBP) are sequestered in aggregates formed by
mutant Ataxin-3 or huntingtin, they can move in and out
of aggregates formed by Ataxin-1 [9]. Thus, localization ofwww.sciencedirect.com
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Table 1
Genes affected by polyglutamine expansion and the function of their protein products where known. In some cases repeat expansion
affects more than one gene product.
Polyglutamine expansion diseases
Disease name Products of
expanded gene
Wild-type number
of repeats (repeat
sequence)
Repeat
expansion
in disease
Protein function
Huntington disease (HD) Huntingtin 6–34 (CAG) 36–121 Transcriptial repressor, membrane
trafficking, endocytosis.
Spinal and bulbar muscular
atrophy (SBMA)/Kennedy’s
disease
Androgen receptor 9–36 (CAG) 38-62 Nuclear receptor, androgen response.
Dentatorubral-pallidoluysian
atrophy
Atrophin 1 7–34 (CAG) 49–88 Nuclear receptor corepressor,
transcriptional corepressor.
SCA1 Ataxin-1, alt-ATXN1 6–39 (CAG) 40–82 RNA processing, transcription factor,
transcriptional corepressor, general
repressor of transcription.
SCA2 and amyotrophic lateral
sclerosis (ALS)
Ataxin-2 15–24 (CAG) 27–33 for
ALS, 32–200
for SCA2
RNA binding protein.
SCA3, Machado-Joseph
disease
Ataxin-3 13–36 (CAG) 61–84 Transcription factor, transcriptional
coactivator, transcriptional repressor,
histone H2B deubiquitinase.
SCA6 a1A
voltage-dependent
calcium channel
subunit, and
a1ACT
4–18 (CAG) 19–33 Voltage-gated calcium channel,
transcription factor.
SCA7 Ataxin-7 4–35 (CAG) 36–460 Integral member of SAGA complex,
regulation of histone acetylation and
ubiquitination.
SCA17 TATA box binding
protein (TBP)
25–42 (CAG) 47–63 General transcription factor,
member of TFIID complex.proteins to nuclear inclusions does not always reflect
functional sequestration, and may not be a common cause
of PolyQ toxicity.
Increasing evidence suggests that PolyQ proteins
regulate gene expression and indeed, many of the 9
CAG-expanded genes are transcription factors, transcrip-
tional coactivators, and regulators of RNA stability
(Figure 1 and Table 1). Furthermore, analysis of gene
expression profiles indicates that a large number of genes
are deregulated in mouse models of polyQ disease [10].
We speculate that deregulation of the transcriptional
program may be central to polyQ disease etiology.
Accordingly, we hypothesize that closer examination of
the transcriptional basis for polyQ disease will yield new
avenues for therapeutic intervention.
Huntington disease
Huntington disease is caused by polyglutamine expan-
sion of the Huntingtin (Htt) protein [11]. Nearly two
decades ago, post-mortem brain samples exhibiting the
initial histological signs of Huntington disease showed
deregulation of transcripts for enkephalin and substance
P before onset of clinical symptoms [12]. These obser-
vations suggested that early changes in transcriptional
regulation contributed to the onset of clinical symptoms.www.sciencedirect.com Subsequently, mouse models for Huntington disease
showed altered expression of genes involved in neuro-
transmission, stress response, and axonal transport before
the onset of disease symptoms, suggesting neural-specific
deregulation of transcriptional control [13]. Among the
many interacting partners of Htt are important transcrip-
tional regulators such as specificity protein 1 (Sp1),
TATA-box-binding protein-associated factor II,
130 kDa (TAFII130) [14], CREB, tumor protein p53
(TP53), SIN3 transcription regulator family member A
(Sin3a) [15], K (lysine) acetyltransferase 2B (KAT2B/
PCAF), CBP, and repressor element 1(RE1)-silencing
transcription factor REST [16]. Although CBP and its
close homolog E1A binding protein p300 (EP300/p300)
are often functionally redundant, and commonly referred
to as CBP/p300, polyQ expanded Huntingtin correlates
with the degradation of only CBP [17]. CBP is associated
with histone H3K27 acetylation, a potential marker for
enhancers that are active but not inactive or poised [18].
Thus, perturbation of gene expression by Htt may occur
through changes in epigenetic marks such as H3K27ac.
Studies suggest that polyQ Htt interferes with transcrip-
tional activation by sequestering transcription factors. For
example, overexpression of Sp1 and TAFII130 rescues
polyQ Htt-mediated inhibition of the dopamine D2Current Opinion in Genetics & Development 2014, 26:96–104
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Table 2
Summary of interactions with focus on known regulators of gene expression and associated chromatin modifications.
Polyglutamine expansion diseases
Disease name Products of
expanded
gene
Associated regulators of gene expression Chromatin modifications associated with
wild-type and/or mutant protein
Huntington disease
(HD)
Huntingtin PolyQ-expanded Huntingtin sequesters
Sp1, TAFII130, CREB, p53, Sin3a, REST,
PCAF, CBP.
In HD, there is decreased CBP-dependent
acetylation, decreased PCAF-associated
acetylation, increased H3K9 methylation
due to increased expression of ESET
methyltransferase.
Spinal and bulbar
muscular
atrophy (SBMA)/
Kennedy’s
disease
Androgen
receptor
The AR itself is a ligand-dependent
transcription factor. Expanded AR is
refractory to hormone signaling and is
preferntially degraded. Like many TFs it can
interact with coactivators such as p160 and
CBP/p300, as well as the basal transcripton
apparatus, including TFIIF and TBP.
In SBMA, histone acetylation is reduced.
During normal AR-mediated gene
expression H3R17 methylation, H3S10
phosphorylation, and H3K4 methylation are
all regulated dynamically.
Dentatorubral-
pallidoluysian
atrophy
Atrophin 1 Atrophin 1 interacts with Sin3A, HDACs, and
the ETO/MTG8 corepressor complex
subunit. Drosophila Atrophin interacts with
histone methyltransferase G9a. Atrophin-1
also interacts with Nedd-4 E3 ubiquitin
ligases, which regulate transcription factors
from SMAD, p53, KLF, RUNX, and Jun
families. Nedd-4 E3 ligases also regulate
transcriptional regulators TGFbeta, EGF,
IGF, VEGF, SDF-1, and TNFalpha.
Histone acetylation. Higher order chromatin
structure appears abberant in DRPLA
patients brain samples.
SCA1 Ataxin-1,
alt-ATXN1
Ataxin-1 and alt-ATXN1 in teract with each
other and with poly(A)(+) RNA. Ataxin-1 is
recruited to the Hey1 promoter by
transcription factor RBPJ-kappa to repress
transcription. PolyQ-expanded Ataxin-1
associates with PQBP-1 and stimulates its
interaction with Pol II, reducing Pol II
phosphorylation and transcription.
Unknown
SCA2 and
amyotrophic lateral
sclerosis (ALS)
Ataxin-2 SCA2 regulates gene expression post-
transcriptionally, by regulating RNA
processing and translation. It interacts with
RNA binding protein A2BP1, RNA helicase
DDX6, and Poly(A) binding protein PABP-
C1.
Unknown
SCA3, Machado-
Joseph
disease
Ataxin-3 Ataxin-3 binds chromatin directly and can
be found in gene promoters. It can activate
and repress transactivation. It is a
deubiquitinase and this activity is
indespensible for transactivation function.
Interacts with FOXO-4, TAFII130, CBP,
NCoR, HDACs, RAD23. PolyQ expansion
reduces Ataxin-3 transcrional repression
function.
H2B poly-ubiquitination, H3ac
SCA6 a1A voltage-
dependent
calcium
channel subunit,
and a1ACT
trascription factor
The a1ACT transcription factor coordinates
expression of many genes involved in neural
and Purkinje cell development. Upon
polyglutamine expansion, a1ACT lacks
transcription factor function yet forms
intranuclear inclusions that colocalize with
the CREB transcription factor [32,33].
Histone acetylation
SCA7 Ataxin-7 Ataxin-7 is a subunit of the SAGA chromatin
modifying complex, which interacts with
many transcription factors, and also
contains the histone acetyltransferase
Gcn5/PCAF, as well as the histone
deubiquitinase USP22.
In SCA7 H3K9ac and H3K14ac are reduced.
The SAGA complex also regulates H2B
ubiquitination and H2A ubiquitination.
Current Opinion in Genetics & Development 2014, 26:96–104 www.sciencedirect.com
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Table 2 (Continued )
Polyglutamine expansion diseases
Disease name Products of
expanded
gene
Associated regulators of gene expression Chromatin modifications associated with
wild-type and/or mutant protein
SCA17 TATA box
binding
protein
(TBP)
TBP is a general transcription factor
involved in expression of a large number of
genes. TBP interacts directly with chromatin
and with other transcriptional regultors such
as: TFIIB and NFY. PolyQ expansion has
been shown to decrease interaction with
chromatin, but increase interaction with
TF’s.
TBP is associated with transcriptional
activation and therefore, chromatin
modifications associated with a
transcriptionally active state. The effect of
PolyQ expansion of TBP on downstream
chromatin marks is not clear.receptor gene, protecting neurons from Htt-induced cel-
lular toxicity [14]. PolyQ Htt can sequester CBP and
PCAF, reducing histone acetylation and expression of
CBP-regulated genes [15,19]. Accordingly, overexpres-
sion of CBP can rescue neuronal toxicity in a mouse
model of Huntington disease [19]. PolyQ Htt also reduces
WT Htt function. For example, Htt normally sequesters
REST in the cytoplasm, preventing repression of the
neuroprotective brain-derived neurotrophic factor
(BDNF). PolyQ Htt disrupts this interaction, reducing
BDNF expression and, consequently, causing loss of
neurons [20]. Wild-type Htt can also interact with methyl
CpG binding protein 2 (MeCP2), resulting in its localiz-
ation to methylated gene promoters and reduced expres-
sion of the downstream genes. PolyQ expansion increasesFigure 1
Transcrip
processin
Transcriptiona
repression
Transcription
coactivation
and direct
chromatin
modification
Ataxin-1
SAGA
Gcn5
Ataxin-7
Ataxin-3USP22
Chromatin
Atrophi
Huntingtin
Histone
acetylation
Histone
deubiquitination
Alt-ATXN
PolyQ disease affects chromatin modification and usage. Chromatin events
Huntingtin, Androgen receptor, Atrophin 1, Ataxin-1, Ataxin-2, Ataxin-3, alph
and TATA box binding protein (TBP) are all important regulators of gene exp
www.sciencedirect.com Htt’s interaction with MeCP2 and its localization to the
BDNF promoter, causing stronger repression of BDNF.
SiRNA-mediated knock-down of MeCP2 alleviates this
effect, restoring expression of BDNF [21]. Thus, PolyQ
Htt reduces BDNF levels through a combination of seques-
tration of the REST transcription factor in the cytoplasm
and stronger repression at the methylated BDNF gene.
Histone methylation is altered in Huntington disease
patient brains through elevated levels of the H3K9 meth-
yltransferase ERG-associated protein with SET domain
(ESET). Although the contribution of altered methylation
and the consequent changes in transcription to polyQ
disease are not clear, the reduction of H3K9 trimethylation
by pharmacological treatments increases lifespan by 40% int
g
Transcriptional
activationl
Ataxin-2
n 1
Alpha1ACT
Androgen
receptor
TBP
Pol II
1
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 are central to polyQ disease. The polyglutamine expanded proteins
a-1a voltage-dependent calcium channel subunit, alpha1ACT, Ataxin-7,
ression and chromatin modification.
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potential therapeutic target in humans [22].
Spinal and bulbar muscular atrophy (SMBA), or
Kennedy’s disease
SBMA is caused by polyglutamine expansion in the trans-
activation domain of the androgen receptor (AR) [23]. AR is
a steroid hormone-dependent transcription factor that binds
to androgen response elements in target genes when associ-
ated with testosterone or dihydrotestosterone. AR then
recruits transcriptional co-activators and promotes gene
expression. Polyglutamine expansion of its glutamine-rich
transactivation domain interferes with AR binding to coac-
tivators such as p160 and components of the basal transcrip-
tion apparatus TFIIF and TBP. It remains to be
determined whether H3R17 methylation, H3S10 phos-
phorylation, and H3K4 methylation, all of which are
regulated dynamically during normal AR-mediated gene
expression, are impacted by its PolyQ expansion [24].
Dentatorubral pallidoluysian atrophy (DRPLA)
DRPLA is caused by polyglutamine expansion of the
gene encoding the atrophin-1 protein, which leads to
significant degeneration in the brain and spinal cord
[25]. Histologically, higher order chromatin architecture
appears to be drastically altered in patient brain samples
[26]. Atrophin-1 is a member of a small family of proteins
that interact with nuclear receptors and function as co-
repressors. The members of this family include Atrophin-
1 and arginine glutamic acid repeats encoded protein
(RERE, or Atrophin-2) in vertebrates, and Atrophin (Atro
or Grunge) in Drosophila [27]. Atrophin-1 can repress
transcription in reporter gene assays and sequesters tran-
scriptional regulators into nuclear matrix-associated
inclusions. Some of these regulators include Sin3A,
histone deacetylases (HDACs), and runt-related tran-
scription factor 1; translocated to, 1 (cyclin D-related)
(RUNX1T1/ETO/MTG8) — a component of nuclear re-
ceptor co-repressor complexes [28]. Atrophin-1 contains
five PY motifs (PPXY) proximal to the region susceptible
to polyglutamine expansion. These motifs interact with
Trp-Trp (WW) domain-containing proteins [29]. Accord-
ingly, atrophin-1 interacting partners include WW
domain containing members of the Nedd-4 family of
E3 ubiquitin ligases. Nedd-4 proteins regulate ubiqui-
tin-mediated trafficking, protein degradation, and nuclear
translocation of various transcription factors [30,31].
In Drosophila, Atrophin binds to the histone methyltrans-
ferase G9a and mediates mono-methylation and di-meth-
ylation of H3K9. In humans, RERE also associates with
G9a to methylate histones. Drosophila Atrophin and
RERE interact with G9a through conserved SANT
(switching-defective protein 3 (Swi3), adaptor 2 (Ada2),
nuclear receptor co-repressor (N-CoR) and transcription
factor (TF)IIIB) domains. Atrophin-1 does not contain a
SANT domain but interacts with RERE, suggesting thatCurrent Opinion in Genetics & Development 2014, 26:96–104 Atrophin-1 and RERE might act together to regulate
histone methylation [32].
Spinocerebellar ataxia 1 (SCA1)
SCA1 is caused by polyglutamine expansion of the Ataxin-1
gene, which encodes two proteins — Ataxin-1 and alt-
Ataxin-1. Alt-Ataxin-1 is produced by an out-of-reading-
frame coding sequence within Ataxin-1. These gene pro-
ducts can interact with each other and with poly(A)(+) RNA
[33]. An early screen performed in Drosophila to identify
modifiers of SCA1-mediated neurodegeneration identified
genes important for RNA processing and transcriptional
regulation, [34]. Ataxin-1 also inhibits transcription from the
Hey1 promoter, a crucial gene in Notch signaling, where it
is recruited through interaction with the recombination
signal binding protein for immunoglobulin kappa J region
(RBPJk) transcription factor [35]. It has also been proposed
that Ataxin-1 plays a general role in transcriptional repres-
sion. Polyglutamine expansion of Ataxin-1 increases its
interaction with poly-glutamine (Q) tract-binding
protein-1 (PQBP-1) which, in turn, stimulates PQBP-1
binding to RNA polymerase II (Pol II) and reduces Pol
II phosphorylation and transcription [36].
Ataxin-1 associates with protein phosphatase 2A (PP2A),
and overexpression of Ataxin-1 in mice stimulates PP2A
activity. However, whereas overexpression of wild-type
Ataxin-1 led to a 59% increase in PP2A activity, over-
expression of polyglutamine-expanded Ataxin-1 resulted
in a 238% increase [37]. PP2A affects H3S10 phosphor-
ylation, and its overexpression causes a genome-wide
reduction in H3 phosphorylation [38]. The effect of
Ataxin-1 PolyQ expansion on H3 phosphorylation has
not been examined.
Spinocerebellar ataxia 2 (SCA2)
Polyglutamine expansion in the Ataxin-2 gene contrib-
utes to two diseases. SCA2 is caused by expansions of 32–
200 CAGs, and intermediate expansions of 27–39 CAGs
were identified as a genetic risk factor for amyotrophic
lateral sclerosis (ALS) [39,40]. At this time, intermediate
expansion of Ataxin-2 is the best-known predictor of ALS
[39]. Ataxin-2 is an RNA binding protein and it regulates
gene expression post-transcriptionally through inter-
actions with mRNA and other RNA-binding proteins.
Among these interactions is the RNA binding protein
Ataxin-2 binding protein 1 (A2BP1), [41]. Ataxin-2 and
A2BP1 interact and colocalize in vivo, but their functional
relationship is unknown. Ataxin-2 also binds to the
DEAD/H-box RNA helicase DDX6, and the poly(A)
binding protein 1 (PABP-C1), both components of
P-bodies and stress granules [42,43]. PABP-C1 also forms
a protein–mRNA complex with Ataxin-2 in polyribo-
somes. In this complex, PABP-C1 and Ataxin-2 bind to
each other and each maintain direct contact with RNA.
Interestingly, polyglutamine expansion does not interfere
with Ataxin-2 assembly with polyribosomes, suggestingwww.sciencedirect.com
The molecular basis for polyglutamine disease Mohan, Abmayr and Workman 101that polyglutamine expansion of Ataxin-2 might interfere
with translational regulation [43]. Recently, it was shown
that Ataxin-2-mediated regulation of PERIOD trans-
lation is required for maintaining circadian clock function
in pacemaker neurons that set daily rhythms for behavior
and synchronize transcriptional rhythms to the circadian
clock organism-wide [44,45]. Sassone-Corsi and co-
workers discuss this process further in this issue.
Spinocerebellar ataxia 3 (SCA3), or Machado-Joseph
disease
SCA3 is caused by polyglutamine expansion of the
Ataxin-3 gene and is the most common inherited
cerebellar ataxia in some populations [46]. The
Ataxin-3 protein is a transcription factor and can bind
directly to gene promoters in chromatin [47]. It is also a
Josephin domain-containing ubiquitin protease that
binds to and deubiquitinates poly-ubiquitin chains on
histone H2B [48]. Ataxin-3 normally interacts with
numerous transcriptional regulators including the fork-
head box O (FOXO)-4 transcription factor, TATA-bind-
ing protein-associated factor TAFII130 [56], CBP [57],
nuclear co-repressor receptor NCoR [49], histone dea-
cetylases [47], and DNA repair protein RAD23 [50].
Thus, it seems capable of recruiting transcriptional
regulators to gene promoters through its interactions
with both DNA binding proteins and non-DNA binding
chromatin regulatory factors. Once there, it can function
to deubiquitinate histone H2B. Interestingly, Ataxin-3
ubiquitin protease activity is indispensable for gene
activation [47].
Upon oxidative stress, Ataxin-3 shuttles with the
FOXO-4 transcription  factor into the nucleus, where
they bind and activate the manganese superoxide dis-
mutase (SOD2) gene promoter. Polyglutamine expan-
sion impairs Ataxin-3 transactivation function by
preventing recruitment of co-activators, and SOD2
expression is reduced in the brains of SCA3 patients
[51]. It is tempting to speculate that histone deubi-
quitination is disrupted in SCA3 and that a balance of
H2B ubiquitination is important for maintenance of
neural stability. Wild-type Ataxin-3 can also recruit
histone deacetylase 3 (HDAC3) and nuclear receptor
corepressor 1 (NCoR) to the matrix metalloproteinase-2
(MMP-2) promoter, resulting in histone deacetylation
and transcriptional repression [47]. PolyQ Ataxin-3
binds chromatin but does not recruit HDAC3 or NCoR,
reducing the HDAC activity of the Ataxin-3-containing
complexes [47] and eliminating repression  of genes such
as MMP2. In addition, bulk H3 acetylation is higher in
cells expressing PolyQ-expanded Ataxin-3 [47]. This
intimate interplay between Ataxin-3, transcription fac-
tors and chromatin modifiers, along with the ability of
Ataxin-3 to deubiquitinate histones, provides ample
opportunity for misregulation of chromatin modifi-
cations in SCA3.www.sciencedirect.com Spinocerebellar ataxia 6 (SCA6)
SCA6 is caused by polyglutamine expansion of the bicis-
tronic calcium channel, voltage-dependent, P/Q type,
alpha 1A subunit (CACNA1A) gene, which encodes two
protein products — the a1A voltage-dependent calcium
channel subunit and the a1ACT transcription factor [52].
Full-length CACNA1A mRNA produces the a1A ion
channel subunit. The a1ACT transcription factor is pro-
duced from a cryptic internal ribosomal entry site (IRES) in
the 30 end of the transcript [52]. Polyglutamine expansion
occurs in both gene products. This expansion does not
perturb calcium channel gating in knock-in studies [53].
However, expression of the expanded a1ACT alone is
sufficient to cause the SCA6 phenotype [54,55–57]. The
a1ACT protein normally coordinates expression of many
genes involved in neural and Purkinje cell development.
PolyQ expanded a1ACT lacks transcription factor activity
yet forms intra-nuclear inclusions that co-localize with the
CREB transcription factor [52,58]. It is unclear whether
the disease phenotype results from the lack of expression
of normal a1ACT target genes or, perhaps, perturbed
expression of CREB target genes.
Spinocerebellar ataxia 7 (SCA7)
SCA7 is the most prevalent SCA disease in Scandinavian
populations and is caused by expansion of the ATXN7
gene, which encodes the Ataxin-7 protein. Ataxin-7 is a
subunit of the chromatin modifying Spt-Ada-Gcn5-Acet-
yltransferase (SAGA) complex. This highly conserved,
multi-protein complex is comprised of approximately 20
subunits and is an essential transcriptional coactivator that
regulates a large number of genes [59]. The complex
bears two histone-modifying activities: the Gcn5/KAT2
acetyltransferase and the ubiquitin specific protease 22
(USP22) deubiquitinase. SAGA acetylates H3K9 and
H3K14, as well as other residues in histone H3 and the
linker histone H1. USP22 deubiquitinates histone
H2Bub and H2Aub, which are important marks for tran-
scription activation and elongation [60,61].
Within the SAGA complex, Ataxin-7 tethers the deubi-
quitinase and histone acetyltransferase (HAT) modules
to each other. Crystal structures of the Saccharomyces
cerevisiae deubiquitinase module have shown that the
amino terminus of Ataxin-7 is embedded within the
module [62,63]. Polyglutamine expansion occurs
within the amino terminus, and the repeat length can
be very large (Table 1) [64]. H3K9 acetylation is
decreased upon polyglutamine expansion of Ataxin-7
[65,66,67], indicating that the expanded protein impairs
the GCN5 activity within the SAGA HAT module. In
some models, deubiquitinase activity is also impaired,
and the level of ubiquitinated histones increases. The
mechanism underlying perturbation of histone deubiqui-
tination upon PolyQ expansion of Ataxin-7 is unknown
[68], including whether the deubiquitinase module
assembles and functions properly.Current Opinion in Genetics & Development 2014, 26:96–104
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SCA17 is caused by polyglutamine expansion of the
TATA box-binding protein (TBP), a general transcrip-
tion factor at the core of the Transcription Factor II D
(TFIID) complex [69]. TBP binds to the TATA box and
facilitates assembly of the RNA polymerase II pre-
initiation complex (PIC). Accordingly, TBP is responsible
for regulation of a large number of genes. Polyglutamine
expansion occurs in the TBP C-terminus and increases its
association with transcription factors that include TFIIB
and NFY [70]. However, DNA binding is reduced,
slowing the rate of transcription complex formation
and, consequently, transcription initiation [71].
Polyglutamine diseases: expanding
possibilities?
It is apparent from the above discussion that these nine
particular genes are expressed in many cell types and
their gene products regulate the expression of a large
number of genes. Intriguingly, the consequences of
interfering with protein function by PolyQ expansion
manifest as very specific disease pathologies. Even within
the brain, different regions appear to be more susceptible
than others. The mechanisms underlying this tissue
specificity of polyglutamine diseases are of major interest
and will be instrumental in developing therapeutic inter-
ventions.
Why do polyglutamine-expansion diseases preferentially
impact neural tissues? It may be that the functions of the
PolyQ expanded proteins are not as important in other
tissues. One mechanism that might explain why the
polyQ disease proteins are more critical to a small subset
of cells, may be that proteins having redundant function
are expressed widely, yet not in these cells, leaving them
particularly susceptible to polyQ expansion. It is also
possible that these proteins have similar biochemical
behaviors in all cells but that the brain and neural tissues
are simply more sensitive to polyQ-dependent changes in
gene regulation. Alternatively, these proteins may play a
unique role in the brain that is disrupted by polyQ
expansion. One speculation is that neurons are simply
more fragile and less resilient to perturbations than other
tissues. It is also possible that defective neural function
may be more apparent clinically, leading to a focus on
neural tissues to exclusion of others. Thus, it is our view
that closely examining the gene regulatory mechanisms
disrupted by polyQ expansion may provide novel insights
into causative events giving rise to disease and in disease
progression.
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